Previse (formerly known as Capsulomics, Inc.), a Baltimore, MD-based medicine solution company, raised $3M in Seed funding.
The round was led by TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and angel investors.The company intends to use the funds to expand commercial operations and to build prospective clinical utility research for creating broad insurance coverage and reimbursement for Esopredict.Led by CEO Daniel Lunz, and Dr. Stephen Meltzer, Chief Medical Officer, Previse is offering Esopredict™, a precision medicine solution that allows gastroenterologists to provide a tailored approach to Barrett’s esophagus treatment. Esopredict™ delivers timely and accurate risk predictions over a 5-year horizon and identifies changes in the DNA methylation levels of four genes, using a sample of a patient’s Barrett’s esophagus cells to provide a result report called the Esoscore™. The Esoscore™ helps determine a patient’s future risk of getting esophageal cancer and will help gastroenterologists determine the appropriate treatment, steps, and surveillance needs for their patients with Barrett’s esophagus.The company’s technology was made possible by grants from the National Institutes of Health (“NIH”) and developed after decades of research by the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine.21/03/2023
